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Rapidly Progressive Pancreatic Lipomatosis 
in a Young Adult Patient with Transfusion-
dependent Myelodysplastic Syndrome
Wei-Ching Lin,1 Jeon-Hor Chen,1* Chien-Heng Lin,2 Wu-Chung Shen1
Pancreatic lipomatosis is defined as deposition of fat cells in pancreatic parenchyma. Although the etiol-
ogy of this condition is still unclear, it is not uncommon in the elderly, obese individuals, and a variety 
of transfusion-dependent hematologic diseases such as β-thalassemia major. Pancreatic lipomatosis as-
sociated with transfusion-dependent myelodysplastic syndrome (MDS) has never been reported. We pres-
ent a 17-year-old male patient with transfusion-dependent MDS. He received transfusion of a total of 
345 units of blood in a period of 18 months but without iron chelating agent. Progressive fatty replace-
ment of the pancreas parenchyma was found by a series of computed tomography images over seven hos-
pital admissions due to repeated infections. Bone marrow biopsy revealed hemosiderin deposition.
Because of his poor response to induction chemotherapy, stem cell transplantation was suggested, but 
the patient died of sepsis before the therapeutic procedure could take place. Although most patients with
pancreatic lipomatosis have neither clinical symptoms nor abnormal laboratory data, it may cause en-
docrine and exocrine pancreas dysfunction. In this reported case, mild exocrine dysfunction was noted on
the last admission. Clinicians should be cautious of hemosiderin deposition after large amount of blood
transfusion and chelating therapy should be given to avoid iron overload. [J Formos Med Assoc 2007;
106(8):676–679]
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Pancreatic lipomatosis is seen in patients with
tumors or stones which obstruct the pancreatic
duct and cause fatty infiltration in the distal por-
tion of the pancreas. Diffuse pancreatic lipo-
matosis is frequently found in the elderly, obese
patients, and sometimes in patients with con-
genital abnormalities and β-thalassemia major.
Myelodysplastic syndrome (MDS) is a hetero-
geneous group of closely related clonal hemato-
poietic disorders. All are characterized by either
hypercellular or hypocellular marrow with impaired
morphology and maturation and pancytopenia in
peripheral blood, resulting from ineffective blood
cell production. Patients with MDS who need re-
peated blood transfusions will develop hemochro-
matosis if no effective chelating therapy is given.
Hemochromatosis refers to iron overload in
various organs, especially in the liver, myocardium
and both endocrine and exocrine glands; the dis-
order can lead to organ dysfunction. The mecha-
nism of MDS-induced pancreatic lipomatosis,
although not understood, is supposed to be the
same as what occurs in transfusion-dependent 
β-thalassemia major patients.
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A 17-year-old boy presented to our outpatient
department with pancytopenia and severe ane-
mia. Pathologic results from bone marrow biopsy
showed refractory anemia with excess of blasts
(RAEB) type of MDS. Chromosome study showed
t(3;21)(q26;q22). The patient was 165cm in height
and weighed 50 kg on admission. His medical
history and results from physical examination
were unremarkable.
The patient had been hospitalized seven times
within 18 months after MDS was diagnosed be-
cause of repeated infections. A total of four abdo-
minal computed tomography (CT) examinations
were performed within the 18-month period to
exclude the occult infectious sources. Multiple ab-
scesses in the spleen and mild fatty replacement of
the pancreas were noted on the first abdominal CT
scan (Figure 1). About 1 month later, the second
abdominal CT showed massive fatty replacement
of the pancreas with scanty amount of residual
glandular tissues and ductal structures (Figure 2).
Further progressive and severe fatty replacement
of the pancreas was demonstrated on the third and
fourth abdominal CT scans (Figures 3 and 4) taken
about 11 months and 18 months after the first CT
scan, respectively.
He had received regular blood transfusions for




Figure 1. The first computed tomography scan with contrast
enhancement of the upper abdomen shows a microab-
scess (black arrow) in the enlarged spleen (S) and a very
mild degree of fat cells interposed between the pancreatic
parenchyma (white arrows).
Figure 4. The residual ductal structure (white arrows) is
visible in the markedly fatty-replaced pancreas in this com-




Figure 2. The second computed tomography scan with
contrast enhancement of the upper abdomen reveals the re-
placement of pancreatic parenchyma by abundant fatty tis-
sue with scanty residual glandular structures (white arrows).
A
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Figure 3. The third computed tomography (CT) scan with
contrast enhancement of the upper abdomen demonstrates
even more massive fatty replacement of the pancreas
(white arrows) than was seen on the second CT scan. Note
also the liver abscess (A) and splenomegaly (S).
The subtotal volumes of red blood cell products
he received before undergoing CT scans were 60
units, 12 units, 108 units, and 174 units, respec-
tively. He was not undergoing iron chelation
therapy and no serum ferritin data were available.
However, hemosiderin deposition was visible in
the bone marrow biopsy specimen.
Throughout the course of the disease, his fast-
ing blood glucose and serum lipase levels were
within normal ranges, although a mildly decreased
serum amylase level (15 U/L) was noted on his
last admission. After the diagnosis of MDS had
been made, the patient underwent induction che-
motherapy with continuous infusion of Ara-C
100 mg/m2/day for 7 days and bolus injection 
of idarubicin 12 mg/m2/day on the first 3 days.
However, the patient responded poorly to induc-
tion chemotherapy, and the treatment was termi-
nated. He was placed on a waiting list for stem
cell transplantation, but the patient died of sepsis
before the therapeutic procedure could take place.
Discussion
Pancreatic lipomatosis is a fatty infiltration or re-
placement of part or all glands of the pancreas;
however, the pathogenesis of the disease is not
well understood. It is not uncommon in the eld-
erly, obese individuals and in some patients with
congenital abnormalities such as Shwachman-
Diamond syndrome and cystic fibrosis. Other
conditions related to diffuse fatty replacement of
the pancreas include diabetes mellitus, steroid
therapy, Cushing’s syndrome, chronic pancreati-
tis, hemochromatosis, and malnutrition.1,2 Main
pancreatic duct obstruction may also lead to fatty
replacement of the distal portion of the pan-
creas.2 Our patient was a tall, thin teenage boy
without any of the above mentioned congenital
or acquired conditions. He did have a history of
massive blood transfusion. Therefore, the most
probable cause of pancreatic lipomatosis in our
patient was hemochromatosis.
In most cases, fatty replacement of the pan-
creas does not cause clinical symptoms; however,
patients with severe cases may present with atyp-
ical abdominal pain, malabsorption and diabetes
mellitus due to exocrine and endocrine dysfunc-
tion. Pancreatic lipomatosis is visible on abdom-
inal sonography, CT and magnetic resonance
imaging (MRI). An increase in the echogenicity of
the pancreas is noted on abdominal sonography.
CT shows more specific fat density in the pancre-
atic bed. MRI reveals a variable sized pancreas
with high signal intensity in both short and long
TR images. Short tau (τ) inversion recovery (STIR)
MRI suppresses fat signals well.2
At one time, transfusional iron overload was
termed hemosiderosis to distinguish it from he-
mochromatosis. The iron loading begins in the
reticuloendothelial (RE) cells when the trans-
fused red cells become senescent and degraded
by the RE cells. Then, as the iron storage capacity
of the RE cells is saturated after transfusion of
about 30–40 units of blood, iron is distributed
to the parenchymal cells of other organs.3 This
iron overload especially affects the liver, myo-
cardium, the pancreas (including both endocrine
and exocrine cells) and other endocrine glands.
The endocrine glands most susceptible to severe
damage are the pancreas, pituitary gland, gonads,
thyroid, and parathyroids.3
Pathologic examination of the pancreas in
transfusion-dependent patients shows that iron
accumulates in the exocrine acinar cells, espe-
cially within the β cells.4,5 It is hypothesized that
when the pancreatic cells die from the cytotoxic
effects of iron, the pancreatic parenchyma is pro-
gressively replaced by inert adipose tissue. Older
patients and patients who have received numer-
ous transfusions have greater iron overload and
have the highest risk of developing pancreatic
lipomatosis.2
Iron loading causes cellular injury because ex-
cessive iron uptake by cells leads to the genera-
tion of reactive oxygen species, especially hydroxyl
radicals, and the formation of hemosiderin-laden
lysosomes. These free radicals are thought to dam-
age cellular enzymes, DNA, polysaccharides, and
the membrane and nuclear membrane of intra-
cellular microorganisms. The hemosiderin-laden
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lysosomes are mechanically fragile and tend to
fracture. After the lysosomes rupture, hydrolases
are released into the cytosol, causing cell lysis and
death.3,6
Our patient had received numerous large
amounts of blood transfusion to treat his refrac-
tory anemia. Chelating therapy was, however, not
given at that time. Nevertheless, rapidly progressive
fatty replacement of the pancreas was found inci-
dentally on abdominal CT. The patient did not
present with any abnormalities, except a mildly de-
creased amylase level noted at the last admission.
The mechanism of fatty replacement in our
patient is believed to be the same as that respon-
sible for fatty replacement in the pancreas of
transfusion-dependent β-thalassemia major pa-
tients. The reason why the process of fatty replace-
ment in his pancreas took place so quickly is not
fully understood. It seems that the rapid process
was initiated when the iron loading reached a cer-
tain threshold. This could account for the marked
fatty replacement of the pancreas which occurred
within such a short period of time in our patient.
Once fatty replacement begins, the process is ir-
reversible, regardless of whether transfusions are
decreased or terminated, or iron chelating therapy
is given. The result is severe exocrine dysfunction
of the pancreas.2
In summary, we have reported a rare case of
transfusion-dependent MDS with severe pancre-
atic lipomatosis. Rapidly progressive replacement
of the pancreatic parenchyma by inert adipose
tissue was most likely due to the cytotoxic effects
of iron in the pancreatic cells. CT affords good
fat-to-residual pancreatic tissue contrast, and is
therefore very reliable for evaluating the progres-
sive fatty change of the pancreas. Clinicians should
be aware of iron overload in patients with chronic
massive blood transfusions and strategies should
be taken to avoid further organ damage.
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